CRIS

Curis Inc

0.6000

Oct 30 • 3:59 PM ET +0.0515 (9.39%)

0.5564

Aftermarket • 7:42 PM ET -0.0436 (-7.27%)

Healthcare Biotechnology USA Nano NASD

Peers: KPTI KURA ATNM CRDF APRE PRLD ACRV TPST GTBP BYSI

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.01M
Enterprise Value	-0.57M
Income	-21.15M
Sales	4.31M
Book/sh	2.41
Cash/sh	0.84
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Aug 01, 2000

P/E	-
Forward P/E	-
PEG	-
P/S	0.93
P/B	0.25
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.13
Quick Ratio	0.49
Current Ratio	0.49
Debt/Eq	0.22
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	-14.29
EPS next Y	-6.01
EPS next Q	-2.67
EPS this Y	-306.38%
EPS next Y	87.24%
EPS next 5Y	15.90%
EPS past 3/5Y	63.80% 45.78%
Sales past 3/5Y	-2.42% -2.71%
EPS Y/Y TTM	85.37%
Sales Y/Y TTM	-62.17%
EPS Q/Q	70.48%
Sales Q/Q	-100.00%
Earnings	Jul 30
EPS/Sales Surpr.	40.38% -100.00%

Insider Own	17.07%
Insider Trans	0.00%
Inst Own	10.10%
Inst Trans	-10.01%
ROA	-87.76%
ROE	-693.93%
ROIC	-450.54%
Gross Margin	97.71%
Oper. Margin	-833.40%
Profit Margin	-490.33%
SMA20	11.37%
SMA50	-34.86%
SMA200	-93.36%
Trades

Shs Outstand	6.68M
Shs Float	5.54M
Short Float	7.93%
Short Ratio	1.29
Short Interest	0.44M
52W High	31.80 -98.11%
52W Low	0.32 84.62%
Volatility	25.29% 17.35%
ATR (14)	0.10
RSI (14)	42.19
Beta	3.24
Rel Volume	2.69
Avg Volume	340.05K
Volume	915,541

Perf Week	55.32%
Perf Month	-27.77%
Perf Quarter	-88.35%
Perf Half Y	-94.93%
Perf YTD	-96.96%
Perf Year	-97.99%
Perf 3Y	-99.28%
Perf 5Y	-99.98%
Perf 10Y	-99.99%
Recom	1.00
Target Price	42.67
Prev Close	0.55
Price	0.60
Change %	9.39%

Consensus

Strong Buy

Avg. Price Target

$42.67

Implied Upside

+7,011.7%

Analysts16incl. previous ratings

Rating Distribution14 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 19, 2025	Resumed	HH.C. Wainwright	Buy	$17	+2,733.3%
Nov 17, 2023	Initiated	TTruist	Buy	$26	+4,233.3%
Apr 04, 2022	Downgrade	RRaymond James	Outperform → Mkt Perform
Oct 13, 2021	Initiated	RRaymond James	Outperform	$15	+2,400.0%
Mar 25, 2021	Initiated	RB. Riley Securities	Buy	$19	+3,066.7%
Jul 29, 2020	Initiated	LLaidlaw	Buy	$5	+733.3%
Jul 17, 2020	Initiated	CCantor Fitzgerald	Overweight	$4	+566.7%
Oct 24, 2017	Initiated	GGuggenheim	Buy	$7	+1,066.7%
Mar 02, 2016	Initiated	SSun Trust Rbsn Humphrey	Buy	$3	+400.0%
Nov 09, 2015	Reiterated	RROTH Capital	Buy	$6 → $5	+733.3%
Aug 11, 2015	Initiated	FFBR Capital	Outperform	$6	+900.0%
Jan 22, 2015	Reiterated	OOppenheimer	Outperform	$3 → $5	+733.3%
Jan 21, 2015	Reiterated	RROTH Capital	Buy	$10 → $6	+900.0%
May 09, 2014	Reiterated	OOppenheimer	Outperform	$4.50 → $3	+400.0%
Oct 02, 2013	Initiated	RRobert W. Baird	Outperform	$7	+1,066.7%
Sep 30, 2013	Initiated	CChardan Capital Markets	Buy	$6	+900.0%
Nov 14, 2012	Initiated	SStifel Nicolaus	Hold
Jan 31, 2012	Reiterated	SSummer Street Research	Buy	$5 → $7	+1,066.7%
Jan 31, 2012	Reiterated	BBrean Murray	Buy	$5 → $6	+900.0%
Dec 09, 2011	Initiated	OOppenheimer	Outperform	$6	+900.0%

Oct-16-26 08:00AM	Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors (PR Newswire) -19.86%
Aug-14-26 04:16PM	Curis: Q2 Earnings Snapshot (Associated Press)
Aug-13-26 08:00AM	Curis, Inc. Announces Pricing of $5.6 Million Public Offering (PR Newswire) +11.98%
Jul-30-26 08:00AM	Curis Doses First Five Patients in TakeAim CLL Study (PR Newswire)
Jul-22-26 08:25AM	Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) (InvestorsHub)
07:00AM	Loading…
07:00AM	Curis Announces Positive Emavusertib Update (PR Newswire)
Jul-06-26 09:30AM	Curis Consents First Six Patients in TakeAim CLL Study (PR Newswire) -14.31%
Jun-29-26 06:37AM	Curis opens 11 sites for emavusertib combo in TakeAim CLL trial (Clinical Trials Arena) +37.69%
Jun-26-26 09:42AM	Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split (PR Newswire) +55.98%
May-13-26 01:02AM	Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ... (GuruFocus.com) -9.16%
May-12-26 04:10PM	Curis: Q1 Earnings Snapshot (Associated Press)
04:00PM	Curis Provides First Quarter 2026 Business Update (PR Newswire)
May-05-26 05:11PM	Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 (PR Newswire) +8.17%
Mar-19-26 11:02PM	Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ... (GuruFocus.com) -7.14%
04:11PM	Curis: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	Curis Provides Fourth Quarter 2025 Business Update (PR Newswire)
Mar-12-26 04:27PM	Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026 (PR Newswire) -5.93%
Jan-09-26 08:00AM	Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds (PR Newswire)
Jan-07-26 08:45AM	Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds (PR Newswire) -15.97%
Dec-09-25 08:00AM	Curis Provides Updated Data from its Frontline AML Triplet Study (PR Newswire)
Nov-14-25 09:26AM	Curis to Present at Upcoming 30th Annual SNO Meeting (PR Newswire) +17.70%
Nov-07-25 12:02AM	Curis Inc (CRIS) Q3 2025 Earnings Call Highlights: Promising Study Results and Financial ... (GuruFocus.com) -10.27%
Nov-06-25 05:10PM	Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:08PM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Curis Provides Third Quarter 2025 Business Update (PR Newswire)
Oct-30-25 04:00PM	Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 (PR Newswire)
Oct-03-25 04:00PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-02-25 10:43AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-06-25 11:00AM	Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Aug-05-25 09:10AM	Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:08AM	Loading…
08:08AM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Second Quarter 2025 Business Update (PR Newswire)
Aug-04-25 10:13AM	Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-29-25 08:30AM	Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025 (PR Newswire)
Jul-02-25 08:32AM	Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement (PR Newswire) -18.60%
May-07-25 03:07AM	Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments (GuruFocus.com) -5.94%
May-06-25 06:16PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -10.61%
09:05AM	Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:13AM	Curis: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides First Quarter 2025 Business Update (PR Newswire)
May-05-25 10:26AM	Curis Inc (CRIS) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-01-25 10:01AM	Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline (Zacks) +17.54%
Apr-29-25 08:00AM	Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025 (PR Newswire)
Apr-12-25 11:00AM	Goldman Sachs, J&J, To Report Earnings As Investors Watch Out For Retail Sales Data (Seeking Alpha)
Apr-02-25 04:05PM	Curis to Present at Upcoming Healthcare Conference in April (PR Newswire) -10.14%
Apr-01-25 03:01AM	Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... (GuruFocus.com) -30.48%
01:42AM	Q4 2024 Curis Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-31-25 09:59AM	Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript (Seeking Alpha) -9.48%
08:16AM	Curis: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Fourth Quarter 2024 Business Update (PR Newswire)
Mar-28-25 04:07PM	Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 (PR Newswire)
Dec-10-24 08:00AM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire)
Nov-15-24 02:37AM	Q3 2024 Curis Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Nov-14-24 09:10AM	Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:09AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2024 Business Update (PR Newswire)
Nov-13-24 07:31AM	Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-07-24 08:00AM	Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 (PR Newswire)
Nov-02-24 11:20AM	Curis price target lowered to $20 from $26 at H.C. Wainwright (TipRanks)
Oct-29-24 06:04AM	Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement (PR Newswire) -5.89%
Oct-09-24 03:42PM	Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... (GuruFocus.com)
Sep-23-24 08:30AM	Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer (PR Newswire)
Sep-17-24 07:30AM	Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference (PR Newswire) +5.11%
Sep-04-24 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-01-24 09:10AM	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.85%
08:07AM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Second Quarter 2024 Financial and Operating Update (PR Newswire)
Jul-25-24 08:00AM	Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 (PR Newswire)
Jul-10-24 07:30AM	Curis to Present at Upcoming Healthcare Conference in July (PR Newswire)
Jul-09-24 12:00PM	What Makes Curis (CRIS) a New Buy Stock (Zacks)
Jul-08-24 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-14-24 04:00PM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire) -17.14%
May-10-24 08:00AM	Curis to Present Updated Data from the TakeAim Leukemia Study (PR Newswire)
May-08-24 11:39AM	Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 12:53PM	CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:08AM	Curis: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides First Quarter 2024 Business Update (PR Newswire)
Apr-30-24 08:00AM	Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 (PR Newswire)
Apr-05-24 08:43AM	Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength? (Zacks)
07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-04-24 07:30AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire) +19.48%
Feb-09-24 10:10AM	Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 08:11AM	Curis: Q4 Earnings Snapshot (Associated Press Finance) +13.42%
08:00AM	Curis Provides Fourth Quarter 2023 Business Update (PR Newswire)
Feb-01-24 08:00AM	Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 (PR Newswire)
Jan-05-24 08:00AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -9.87%
Dec-12-23 08:00AM	Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study (PR Newswire) +5.61%
Dec-11-23 08:00AM	Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference (PR Newswire) -8.89%
Dec-06-23 08:00AM	Curis Announces Three Presentations at ASH (PR Newswire) +16.50%
Dec-05-23 08:00AM	Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma (PR Newswire)
Nov-03-23 10:26AM	Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year (GuruFocus.com)
Nov-02-23 08:19AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2023 Business Update (PR Newswire)
Oct-30-23 10:00AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.35%
Oct-26-23 08:30AM	Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 (PR Newswire)
Oct-06-23 08:56AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAITIN KENNETH I	Director	Mar 31 '26	Buy	0.55	10,000	5,487	11,407	Apr 01 07:51 AM

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

PresidentMr. James E. Dentzer

M.B.A.Ms. Diantha Duvall CPA

Chief Development OfficerDr. Jonathan B. Zung Ph.D.

Vice President of Technology Management & Intellectual PropertyMr. Mark W. Noel

Senior Director of Human ResourcesMs. Rachel Blasbalg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRIS

Curis Inc

Upgrade your Finviz experience